Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.

Front Immunol · 2025 · PMC12179661 · PMID 40547042

Europe PMC DOI

hedged sentence

0.0903

closest p · 1.8× alpha

0.0903

boldest claim

The sentences

did not reach statistical significancep=0.0903so close (0.05 < p ≤ 0.1)

Telitacicept-treated animals also had increased muscle AChR content compared to the PBS-EAMG group though it did not reach statistical significance (p=0.0903).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.